

8. Butler J, Anker SD, Packer M. Redefining Heart Failure With a Reduced Ejection Fraction. *JAMA*. 2019;322(18):1761-1762.
9. Peters AE, Clare RM, Chiswell K, et al. Echocardiographic Features Beyond Ejection Fraction and Associated Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. *Circulation: Heart Failure*. 2023;16(5):e010252.
10. Lopatin Y. Heart Failure with Mid-Range Ejection Fraction and How to Treat It. *Card Fail Rev*. 2018;4(1):9-13.
11. Táborský M, et al. *Kardiologie – IV. Srdeční selhání*. 1. vydání. Grada: Praha 2021: 1-4, 20-29, 327-339 ISBN 978-80-271-1439-9.
12. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J*. 2006;27(19):2338-2345.
13. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *The Lancet*. 2012;380(9851):1387-1395.
14. Solomon SD, McMurray JVV, Anand IS, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine*. 2019;381(17):1609-1620.
15. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin–Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. *Journal of the American College of Cardiology*. 2023;82(1):1-12.
16. Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. *European Heart Journal*. 2023;44(31):2982-2993.
17. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. *New England Journal of Medicine*. 2014;370(15):1383-1392.
18. Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. *European Journal of Heart Failure*. 2017;19(11):1495-1503.
19. Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. *European Journal of Heart Failure*. 2017;19(11):1495-1503.
20. Armstrong PW, Lam CSP, Anstrom KJ, et al. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFPEF Randomized Clinical Trial. *JAMA*. 2020;324(15):1512-1521.
21. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *New England Journal of Medicine*. 2021;385(16):1451-1461.
22. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. *Nat Med*. 2022;28(3):568-574.
23. Solomon SD, McMurray JVV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *New England Journal of Medicine*. 2022;387(12):1089-1098.
24. Chatur S, Vaduganathan M, Claggett B, et al. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. *European Heart Journal*. 2023;44(31):2930-2943.
25. Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. *The Lancet*. 2022;400(10369):2199-2209.
26. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. *Lancet*. 2020;396(10266):1895-1904.
27. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. *New England Journal of Medicine*. 2009;361(14):1329-1338.
28. Tang ASL, Wells GA, Talajic M, et al. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. *New England Journal of Medicine*. 2010;363(25):2385-2395.
29. Vijayaraman P, Pokharel P, Subzposh FA, et al. His-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy (HOT-CRT) versus Biventricular Pacing. *JACC: Clinical Electrophysiology*. 0(0).
30. Vijayaraman P, Sharma PS, Cano Ó, et al. LB-456088-1 Left bundle branch area pacing compared to biventricular pacing for cardiac resynchronization therapy: results from international LBBAP collaborative study group. *Heart Rhythm*. 2023;20(7):1094-1095.
31. Rao IV, Burkhoff D. Cardiac contractility modulation for the treatment of moderate to severe HF. *Expert Review of Medical Devices*. 2021;18(1):15-21.
32. Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. *JACC: Heart Failure*. 2018;6(10):874-883.
33. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Accessed September 17, 2023.

# Tip na dárek pro zdravotníky

Potěšte své přátele a blízké z řad lékařů či farmaceutů předplatným některého z oblíbených časopisů vydavatelství Solen.



**NÁVOD, JAK  
POSTUPOVAT**



Pro obdarovaného  
si vytisknete dárkový certifikát.